Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2012
04/24/2012US8163305 Targeted cross-linked nanoparticles and their use in vivo gene delivery
04/24/2012US8163303 Nutritional composition for the treatment of pressure ulcers
04/24/2012US8163296 Dimensional analysis of saccharide conjugates with GPC and SEC-MALS
04/24/2012US8163288 S. aureus polypeptides and antibodies
04/24/2012US8163281 Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
04/24/2012US8163278 Administering secretin based on chymotrypsin level; attention deficit disorder, hyperactivity, autism
04/24/2012US8163277 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants
04/24/2012CA2671383C Dried composition
04/24/2012CA2614171C Copolymers for suppression of autoimmune diseases, and methods of use
04/24/2012CA2542834C Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
04/24/2012CA2517544C Clostridial neurotoxins for treating uterine disorders
04/24/2012CA2499496C Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity
04/24/2012CA2485959C Polypeptide cleavage process
04/24/2012CA2473469C Tolerogenic peptides from myelin basic protein
04/24/2012CA2472190C Composition comprising at least an oxazolin for inhibiting langerhans cell migration, and uses thereof
04/24/2012CA2466244C Methods and apparatus for production of a micro-organ
04/24/2012CA2439570C In-situ gel formation of pectins
04/24/2012CA2433582C Peptides having inhibiting activity on the production of nitric oxide
04/24/2012CA2431557C Derivatives of streptogramins, their preparation and compositions containing them
04/24/2012CA2425599C Fumaric acid amides
04/24/2012CA2414609C Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
04/24/2012CA2408752C Delivery systems for treatment of vascular disease
04/24/2012CA2339529C Isolated and purified human soluble guanylyl cyclase .alpha.1/.beta.1 (hsgc .alpha.1/.beta.1)
04/24/2012CA2277141C Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
04/19/2012WO2012051581A2 Intestinal peptide targeting ligands
04/19/2012WO2012051567A2 Obesity-related genes and their proteins and uses thereof
04/19/2012WO2012051556A1 Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide
04/19/2012WO2012051518A2 Compounds and methods for treating or preventing disease conditions associated with alpha-1-antitrypsin
04/19/2012WO2012051459A1 Nucleic acid delivery compounds
04/19/2012WO2012051458A1 Nucleic acid delivery compounds
04/19/2012WO2012051457A1 Nucleic acid delivery compounds
04/19/2012WO2012051447A1 Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
04/19/2012WO2012051415A2 Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
04/19/2012WO2012051247A2 Egfr-based peptides
04/19/2012WO2012051106A1 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
04/19/2012WO2012050978A1 Formulations of ubiquinol and resveratrol esters
04/19/2012WO2012050930A2 Engineered polypeptides having enhanced duration of action
04/19/2012WO2012050925A2 Highly soluble leptins
04/19/2012WO2012050921A2 Nd2 peptides and methods of treating neurological disease
04/19/2012WO2012050892A2 Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
04/19/2012WO2012050850A1 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
04/19/2012WO2012050822A1 Uses of macrophage mannose receptor to screen compounds and uses of these compounds
04/19/2012WO2012050714A2 Cartilage oligomeric matrix protein (comp)-growth factor complexes and uses thereof
04/19/2012WO2012050695A1 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
04/19/2012WO2012050673A1 Methods for the treatment of x-linked hypophosphatemia and related disorders
04/19/2012WO2012050611A2 Aptamers to glycoprotein vi
04/19/2012WO2012050402A2 Cell-permeable recombinant parkin protein and a pharmaceutical composition for treating degenerative brain diseases containing the same
04/19/2012WO2012050374A2 Immunotherapy for solid tumors
04/19/2012WO2012050303A2 Pharmaceutical composition for cancer prevention and treatment containing the c12orf59 gene or protein as an active ingredient
04/19/2012WO2012050193A1 Ebola virus liposome vaccine
04/19/2012WO2012050184A1 Sustained-release pharmaceutical composition
04/19/2012WO2012049636A1 Eif6 phosphorylation antagonists for use in medicine
04/19/2012WO2012049430A2 Hydrolysates of animal proteins of marine origin with neuroprotective properties
04/19/2012WO2012049332A1 Peptides and uses
04/19/2012WO2012049324A2 New emd formulation comprising pga
04/19/2012WO2012049312A1 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
04/19/2012WO2012049310A1 Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
04/19/2012WO2012049245A1 Method for purification of complement factor h
04/19/2012WO2012049215A1 Antimicrobial protein
04/19/2012WO2012048893A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
04/19/2012WO2012048721A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
04/19/2012WO2012048667A1 Epidermal growth factor receptor variant lacking exon
04/19/2012WO2012048653A1 Long-life interferon fusion protein and use thereof
04/19/2012WO2012021796A3 Novel cyclosporin derivatives for the treatment and prevention of a viral infection
04/19/2012WO2012015692A3 Recombinantly expressed insulin polypeptides and uses thereof
04/19/2012WO2012013742A3 Stabilization of fsh
04/19/2012WO2012006329A3 Apoe4 and apoj biomarker-based prevention and treatment of dementia
04/19/2012WO2012004416A3 Treatment of a disease associated with retinal degenerative disorder
04/19/2012WO2012003516A3 Preservative-free follicle stimulating hormone solution delivery device
04/19/2012WO2012003452A3 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function
04/19/2012WO2011163669A3 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
04/19/2012WO2011163646A3 Methods for detection, diagnosis and selective eradication of neoplasms and circulating tumor cells using multidomain biotags
04/19/2012WO2011163637A3 Protein transduction domains mimics
04/19/2012WO2011163394A9 Compstatin analogs for treatment of neuropathic pain
04/19/2012WO2011163312A3 Improving efficacy of cancer therapy
04/19/2012WO2011163308A3 Compositions and methods for preventing and treating organ injury and/or dysfunction
04/19/2012WO2011159970A3 Method for predicting a therapy response in subjects with multiple sclerosis
04/19/2012WO2011159771A3 Compositions and methods for treating cancer
04/19/2012WO2011156774A3 Multivalent glycopeptide constructs and uses thereof
04/19/2012WO2011156736A3 Targeted mucosal treatment of obesity and diabetes
04/19/2012WO2011156453A3 Therapeutic peptides
04/19/2012WO2011155727A3 Method for preventing and treating infection caused by salmonella choleraesuis or salmonella dublin
04/19/2012WO2011153525A9 Methods for treatment of nephrotic syndrome and related conditions
04/19/2012WO2011153512A3 Use of compounds with thrombopoietic activity to promote bone growth and healing
04/19/2012WO2011153491A3 Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
04/19/2012WO2011152662A9 Ptd-uqcrb fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same
04/19/2012WO2011150418A3 Compositions and methods for treating pathologies
04/19/2012WO2011150127A3 Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
04/19/2012WO2011150094A3 Tumor suppression compositions
04/19/2012WO2011149310A3 Peptide for inhibiting interaction between rankl and rank, and pharmaceutical composition containing same
04/19/2012WO2011146922A3 Materials and methods for treatment of inflammation
04/19/2012WO2011146518A9 Pegylated c-peptide
04/19/2012WO2011144674A3 PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
04/19/2012WO2011133566A3 Repairing bruch's membrane with hydrogels
04/19/2012WO2011130618A3 Compositions and methods for producing glycosylated human pdx-1 protein and methods of use therefore
04/19/2012WO2011127393A3 Variants of ancestral uricases and uses thereof
04/19/2012WO2011127202A3 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
04/19/2012WO2011126864A3 Cancer treatment with recombinant vector
04/19/2012WO2011123826A3 Prevention and treatment of cast nephropathy
04/19/2012WO2011122916A3 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene